SCHEMBL5243128

SCHEMBL5243128

CC(c1ccccc1)n1c(=O)[nH]c2cc(Nc3ccccc3)ccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.51
ERCC1 P07992 1/20 0.48
DNASE1 P24855 1/20 0.48
FEN1 P39748 1/20 0.48
ERCC4 Q92889 1/20 0.48
APP P05067 1/20 0.45
MAPK1 P28482 3/20 0.41
B3GNT2 Q9NY97 2/20 0.41
USP1 O94782 1/20 0.40
MDM2 Q00987 3/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2B6 P20813 1/20 0.40
CYP26A1 O43174 1/20 0.39
OPRM1 P35372 1/20 0.39
LMNA P02545 2/20 0.36
ALDH1A1 P00352 1/20 0.36
THRB P10828 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
ALOX12 P18054 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5242312 0.86 POLB (0.52) POLBERCC1DNASE1FEN1ERCC4
SCHEMBL5243743 0.81 POLB (0.53) POLBERCC1DNASE1FEN1ERCC4
SCHEMBL14828721 0.79 POLB (0.70) POLBMAPK1USP1OPRM1ALDH1A1
SCHEMBL5240736 0.79 POLB (0.48) POLBERCC1DNASE1FEN1ERCC4
SCHEMBL14339623 0.78 LMNA (0.55) POLBERCC1DNASE1FEN1ERCC4
SCHEMBL5245528 0.77 ERCC1 (0.51) POLBERCC1DNASE1FEN1ERCC4
SCHEMBL5243046 0.76 ERCC1 (0.52) POLBERCC1DNASE1FEN1ERCC4
SCHEMBL5240690 0.76 POLB (0.47) POLBERCC1DNASE1FEN1ERCC4
SCHEMBL5243422 0.75 ERCC1 (0.46) POLBERCC1DNASE1FEN1ERCC4
SCHEMBL5240740 0.74 MEN1 (0.62) POLBERCC1DNASE1FEN1ERCC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115644-B2 Heterocyclic compounds BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2006-10-03 US claimed
EP-1539708-B1 BENZIMIDAZOLONES AND THEIR USE AS CYTOKINE INHIBITORS BOEHRINGER INGELHEIM PHARMA (US) 2007-12-26 EP disclosed
EP-1539708-B1 BENZIMIDAZOLONES AND THEIR USE AS CYTOKINE INHIBITORS BOEHRINGER INGELHEIM PHARMA (US) 2007-12-26 EP disclosed
US-7115644-B2 Heterocyclic compounds BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2006-10-03 US disclosed
US-20040192748-A1 Heterocyclic compounds BOEHRINGER INGELHEIM PARMACEUTICALS, INC. 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192748-A1 Heterocyclic compounds IL1B, CCL5, IL4 POLB 2544/4885ERCC1 3738/4885DNASE1 2763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.